Purkinje triggers of ventricular fibrillation in patients with hypertrophic cardiomyopathy

• Published in: Journal of cardiovascular electrophysiology Vol. 32; no. 11; pp. 2987 - 2994
• Main Authors: Hocini, Mélèze, Ramirez, F. Daniel, Szumowski, Łukasz, Maury, Philippe, Cheniti, Ghassen, Duchateau, Josselin, Pambrun, Thomas, Derval, Nicolas, Sacher, Frédéric, Cochet, Hubert, Jaïs, Pierre, Haïssaguerre, Michel
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc 01-11-2021
• Subjects: Ablation; Cardiac arrhythmia; Cardiomyopathy; catheter ablation; Catheters; Computed tomography; Defibrillators; Drug therapy; Fibrillation; hypertrophic cardiomyopathy; Hypertrophy; Myocardium; Patients; Radiofrequency ablation; sudden cardiac death; Ventricle; ventricular fibrillation
• ISSN: 1045-3873; 1540-8167
• DOI: 10.1111/jce.15231

Introduction
Ventricular fibrillation (VF) is the main mechanism of sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). The origin of VF and the success of catheter ablation to eliminate recurrent episodes in this population are poorly understood.
Methods and Results
From 2010 to 2014, five patients with HCM (age 21 ± 9 years, three female) underwent invasive electrophysiological studies and ablation at our center after resuscitation from recurrent (9 ± 7) episodes of VF. Ventricular premature beats (VPBs), seen to initiate VF in certain cases, were recorded noninvasively before the ablation procedure. Postprocedural computed tomography (CT) was performed to correlate ablation sites with myocardial hypertrophy in three patients. Outcomes were assessed by clinical follow‐up and implantable cardioverter‐defibrillator interrogations. VPB triggers were localized invasively to the distal left Purkinje conduction system (left posterior fascicle [2], left anterior fascicle [1], and both fascicles [2]). All targeted VF triggers were successfully eliminated by radiofrequency ablation in the left ventricle. Among patients with postablation CT imaging, 93 ± 12% of ablation sites corresponded to hypertrophied segments. Over 50 ± 38 months, four of five patients were free from primary VF without antiarrhythmic drug therapy. One patient who had 13 episodes of VF before ablation had a single recurrence.
Conclusion
In our study of patients with HCM and recurrent VF, VF was not initiated from the myocardium but rather from Purkinje arborization. These sources colocalized with the hypertrophic substrate, suggesting electromechanical interaction. Focal ablation at these sites was associated with a marked reduction in VF burden.